After graduation I started to work at Medical University of Silesia, where I completed my PhD thesis on genetic polymorphisms in coronary artery disease. Selected risk factors for development of arterial ischemic stroke in children were also in the area of my scientific interests. Besides, I am also interested in diagnosis and treatment of other neurological disorders in children: schizencephaly, headache, epilepsy and cerebral palsy. Nine years ago, when I moved to the Department of Pharmaceutical Technology I started the research concerning the technology for the manufacturing and optimization of micro- and nanocarriers of active substances. In addition, I am involved in analyses of rheological parameters of semi-solid preparations.

Research Interest: developmental neurology, neuroscience, genetics, pharmaceutical technology, nanotechnology, biochemistry

Grants: I participated in a multi-center Polish scientific grant and in several academic grants. In 2017, I was a supervisor of a grant of Medical University of Silesia regarding the release of active substances from semi-solid bases.

List of Publications:
Selected articles of my authorship:
1. Beata Sarecka-Hujar, Ilona Kopyta. Poststroke epilepsy: current perspectives on diagnosis and treatment. Neuropsychiatr.Dis.Treat. 2019; Vol.15, p.95-103

2. Joanna Sordyl, Ilona Kopyta, Beata Sarecka-Hujar, Tomasz Francuz, Paweł Matusik, Ewa Małecka-Tendera. Lipid levels and selected biomarkers of vascular changes in children with idiopathic headaches - a preliminary report. Arch.Med.Sci. 2019; Vol.15, No.1, p.120-125

3. Beata Sarecka-Hujar, Andrzej Jankowski, Aneta Ostróżka-Cieślik, Radosław Balwierz, Anna Banyś, Renata Dyja, Dariusz Łukowiec, Dominik Marciniak, Janusz Pluta. Assessment of release of trimetazidine hydrochloride from orally disintegrating tablets (ODTs) prepared using different disintegrants. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.3, p.697-704

4. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar, Tomasz Krzykawski, Jagna Karcz, Anna Banyś, Andrzej Jankowski. Application of selected diffractive and microscopic methods to evaluate the physical state of drug and morphology of microspheres obtained by spray drying of furosemide with Eudragit L30 D-55. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.3, p.759-765

5. Beata Sarecka-Hujar, Ilona Kopyta, Michał Skrzypek. Is the 1298A>C polymorphism in the MTHFR gene a risk factor for arterial ischaemic stroke in children? The results of meta.analysis. Clin.Exp.Med. 2018; Vol.18, No.3, p.337-345. 

6. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar, Andrzej Jankowski. Physicochemical characteristics of furosemide incorporated Eudragit microspheres formulated by spray drying. Acta Pol.Pharm.-Drug Res. 2018; Vol.75, No.6, p.1369-1376

7. Beata Sarecka-Hujar, Radosław Balwierz, Aneta Ostróżka-Cieślik, Renata Dyja, Dariusz Łukowiec, Andrzej Jankowski. Scanning electron microscopy and X-ray energy dispersive spectroscopy - useful tools in the analysis of pharmaceutical products. J.Phys.: Conf.Series 2017; Vol.931, 012008, p.1-5

8. Andrzej Jankowski, Renata Dyja, Beata Sarecka-Hujar. Dermal and transdermal delivery of active substances from semisolid bases. Indian J.Pharmaceut.Sci. 2017; Vol.79, No.4, p.488-500

9. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar. The use of nanotechnology in modern pharmacotherapy. In: Multifunctional systems for combined delivery, biosensing and diagnostics. / Editors: Alexandru Mihai Grumezescu, Amsterdam: Elsevier Inc., 2017, p. 139-158, ISBN: 978-0-323-52725-5

10. Aneta Ostróżka-Cieślik, Beata Sarecka-Hujar. Perspectives of the carbon nanoparticles use in cancer therapy and imaging. Post.Biol.Kom. 2017; T.44, nr 2, s.171-184

11. Dorota Raczkiewicz, Beata Sarecka-Hujar, Alfred Owoc, Iwona Bojar. Cognitive functions and serum cortisol concentration in perimenopausal and postmenopausal women working non-manually. Neuroendocrinol.Lett. 2017; Vol.38, No.4, p.269-274

12. Dorota Raczkiewicz, Alfred Owoc, Beata Sarecka-Hujar, Iwona Bojar. Pain involving the motor system and serum vitamin D concentration in postmenopausal women working in agriculture. Ann.Agric.Environ.Med. 2017; Vol.24, No.1, p.151-155

13. Beata Sarecka-Hujar, Ilona Kopyta, Michał Skrzypek, J. Sordyl. Association between the 20210G>A prothrombin gene polymorphism and arterial ischemic stroke in children and young adults - two meta-analyses of 3586 cases and 6440 control subjects in total. Pediatr.Neurol. 2017; Vol.69, p.93-101

14. Beata Sarecka-Hujar, Aneta Ostróżka-Cieślik, Anna Banyś. Determinants of telemedicine development in health care system. Ann.Acad.Med.Siles. 2016; Vol.70, s.214-219

15. Ilona Kopyta, Paweł Niemiec, Anna Balcerzyk, Ewa Emich-Widera, Ewa Pilarska, Karolina Pienczk-Recławowicz, Marek Kaciński, Janusz Wendorff, Tomasz Nowak, Tomasz Iwanicki, Beata Sarecka-Hujar, Iwona Żak. Fibrinogen alpha and beta gene polymorphisms in pediatric stroke - Case-control and family based study. Eur.J.Paediatr.Neurol.2015; Vol.19, No.2, p.176-180

16. Ilona Kopyta, Mikołaj Zimny, Beata Sarecka-Hujar. The role of biochemical risk factors in the etiology of AIS in children and adults. Int.J.Neurosci.2015; Vol.125, No.12, p.875-884

17. Anna Banyś, Beata Sarecka-Hujar, Andrzej Jankowski, Monika Zalewska. Impact of base type on diclofenac sodium release from semi-solid dosage forms. Ann.Acad.Med.Siles. 2014; Vol.68, No.1, s.1-8

18. Ilona Kopyta, Beata Sarecka-Hujar, Joanna Sordyl, Ryszard Sordyl. The role of genetic risk factors in arterial ischemic stroke in pediatric and adult patients: a critical review. Mol.Biol.Rep. 2014; Vol.41, No.7, p.4241-4251

19. Beata Sarecka-Hujar, Iwona Żak, Ewa Emich-Widera et al. Association analysis of the E-selectin 98G>T polymorphism and the risk of childhood ischemic stroke. Cell Biochem. Funct. 2010; 28: 591-596.

20. Ilona Kopyta, Beata Sarecka-Hujar, Ewa Emich-Widera et al. Association between lipids and fibrinogen levels and ischemic stroke in the population of the Polish children with arteriopathy and cardiac disorders. Wiad. Lek. 2010; 63:17-23.  

21. Zak I, Sarecka-Hujar B, Kopyta I et al. The T allele of the 677C>T polymorphism of methylenetetrahydrofolate reductase gene is associated with an increased risk of ischemic stroke in Polish children. J Child Neurol. 2009; 24: 1262-1267. 

22. Sarecka-Hujar B, Zak I, Krauze J. Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease. Clin Exp Med. 2009; 9: 117-124.

Research Interest: Drug Metaboilism, Mass spectrometry, Pharmacokinetics and Pharmacodynamics, Medicine, Pharmacy.

Research Interest: Medicinal chemistry, Structure-activity relationship studies, Synthesis of heterocyclic compounds, Antimicrobial screening, Enzymatic studies.

Research Interest: Pharmaceutics, Pharmaceutical Sciences, Drugdelivery, Inhalation, Dosage forms, Particle engineering.

Research Interest: Design, Synthesis and qualitative SAR of new anticonvulsant agents acting as non-competitive AMPA receptor antagonists (In collaboration with Dr. Li Niu, Chemistry Department, University at Albany, SUNY, Albany NY), Identifications and synthesis of new anti-cancer agents, Design and synthesis of peptidomimetics as protease inhibitors.

Research Interest: Cardiovascular pharmacology, New Therapeutic targets for atherosclerosis, hypertension and vasculogenesis, Screening of TCM and ethnic drugs.

Research Interest: Therapeutic relevance of plant-derived compounds in the field of the gastrointestinal pathologies (IBD, cancer, etc.) and on the signal transduction mechanisms involved in their action.Moreover, Toxicological aspects of natural products are also studied.

Research Interest: Biomaterials, Nanomedicine, Pharmaceutical Nanotechnology, Nanovaccines, Targeted drug delivery, Nanotoxicity, surface biofunctionalization, Cell-nanoparticle Interactions.

Research Interest: Targeting drug delivery systems (TDDS), Multifunctional nanocarriers or macromolecules have many advantages for diseases treatments. Our lab employs diverse targeting delivery systems including conjugate, liposomes and micelles to deliver anticancer drug or gene for tumor therapy. In this process, we unitize stimuli-responsive strategies (e.g. enzyme-responsive) to obtain the targeting therapy of tumor. Cell-penetrating peptides (CPPs) are also adopted to cross cellular barriers. Internalization mechinisms of CPPs or CPP-cargoes are also focused by us.

Research Interest: Synthesis of nitrogen- and sulfur-containng heterocycles, Design and synthesis of Novel anticonvulsant, Anticancer, Antibacterial and anti-toxoplasmosis drugs, Computer-aided drug Design, Chromatographic techniques for the analysis of the newly ynthesized compounds, (Q)SAR sudies.

Research Interest: Natural drug discovery, Isolation, Physiological and pharmacological characterization of venom/toxin peptides and proteinswith animal tissues, Natural peptides and proteins analytical Chemistry, Mass spectrometry analysis, Molecular biology, Synthetic peptide analogues and their interaction with antibodies and receptors, Identification of novel drug targets, Biomarkers, Ion channel.

Research Interest: Ophthalmology, Cataract Surger,Cornea, Refractive Eye Surgery, Keratoconus.

Research Interest: Outcomes of interventions in public health (health promotion, health services and disease, prevention).

Research Interest: Method development and validation of biosensors for estimation of Cancer Markers.